The bipartisan deal to stabilize the Affordable Care Act (ACA) may get a vote. The New York Times reported that Senate Majority Leader Mitch McConnell, R-Kentucky, indicated that he would be willing to bring the proposal to the floor for debate and a vote. However, McConnell wants to know that the president supports the bill and will sign it into law if it lands on his desk. The deal has support from lawmakers in both parties and Senate Minority Leader Chuck Schumer, D-New York, has indicated that the deal has a majority.
Not only are senators working to stabilize the law, but the Internal Revenue Service (IRS) is still enforcing one of the most controversial aspects of it. Despite what the president has said, the IRS has said it will still enforce a tax penalty on people who do not have health insurance. On his first day in office, the president had signed an executive order instructing agencies to scale back the regulations of the ACA. However, the IRS is still operating under the rules of the ACA.
With no new funding authorized for the Children’s Heath Insurance Programs, states are facing the difficult decision to roll back coverage. Politico reported that states are so far relying on short-term patches, but 6 states and the District of Columbia will quickly run out of funding by the end of the year. If the funding runs out, many enrollees would be moved over to Medicaid, but some will be at risk of losing coverage altogether.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More